dr vokes Recording 1760x900

(50:6)

Dr. Vokes on Different Settings in Head and Neck Cancer

(59)

Dr. Vokes Discusses 2022 ASCO Annual Meeting

(1:25)

Dr. Vokes on Investigative Biomarkers of Response to Checkpoint Inhibitors in Cancer

(2:12)

Dr. Vokes Discusses the Administration of Multimodality Therapy for Lung Cancer

(1:40)

Dr. Vokes on Moving Immunotherapy into Frontline for Head and Neck Cancer

(57)

Dr. Vokes on the Treatment Landscape of Recurrent Head and Neck Cancer

(1:11)

Dr. Vokes on Nivolumab, Pembrolizumab Approvals in Head and Neck Cancer

(1:58)

Dr. Vokes on the Standard of Care for Stage III NSCLC

(2:7)

Voddie Baucham: Do Not Love the World

(40:20)

Chris Voss: How to Succeed at Hard Conversations

(2:53:29)

VW Virtus Malayalam Review | രസങ്ങൾ രഹസ്യങ്ങൾ | Najeeb

(19:7)

FIXING OUR HOTTUB!!

(7:12)

TRACO 2018 - Non-small cell lung cancer and Genomics

(1:51:20)

Inquiry and Impact: The University of Chicago

(10:10)

Evolution of Oncology | Functional Forum January 2017

(1:36:49)

Immunotherapy Advances in Small Cell Lung Cancer

(27:8)

NSCLC: Integrating EGFR-Inhibiting Therapies into Clinical Pathways for First-Line Treatment

(37:23)

PARP-inhibitors: A New Generation of Cancer Drugs

(3:12)

Dr. Vokes on Recent Progress in the Treatment Landscape of Head and Neck Cancer

(1:)

Welcome by Dr. Everett Vokes, CDRP 10th Annual Symposium

(5:24)

Dr. Vokes on Curative Treatment Approaches in Head and Neck Cancer

(1:8)

Dr. Vokes Discusses Patient Characteristics and Immunotherapy in NSCLC

(1:12)

Dr. Vokes on PARP Inhibitors for NSCLC

(1:16)

Dr. Vokes Discusses Unanswered Questions from the PACIFIC Trial in NSCLC

(1:42)

Dr. Vokes on Cetuximab for Head and Neck Cancer

(1:31)

Dr. Vokes on Screening, Epidemiology, and Smoking in Lung Cancer

(1:42)

Dr. Vokes on Biomarker Selection in Head and Neck Cancer

(42)

Dr. Vokes on Selecting Nivolumab or Pembrolizumab for Head and Neck Cancer Treatment

(40)

Dr. Vokes on Pembrolizumab Plus Chemotherapy and Radiation in Lung Cancer

(1:54)